On Bayesian methods of exploring qualitative interactions for targeted treatment

Providing personalized treatments designed to maximize benefits and minimizing harms is of tremendous current medical interest. One problem in this area is the evaluation of the interaction between the treatment and other predictor variables. Treatment effects in subgroups having the same direction but different magnitudes are called quantitative interactions, whereas those having opposite directions in subgroups are called qualitative interactions (QIs). Identifying QIs is challenging because they are rare and usually unknown among many potential biomarkers. Meanwhile, subgroup analysis reduces the power of hypothesis testing and multiple subgroup analyses inflate the type I error rate. We propose a new Bayesian approach to search for QI in a multiple regression setting with adaptive decision rules. We consider various regression models for the outcome. We illustrate this method in two examples of phase III clinical trials. The algorithm is straightforward and easy to implement using existing software packages. We provide a sample code in Appendix A. Copyright © 2012 John Wiley & Sons, Ltd.

[1]  J. MacQueen Some methods for classification and analysis of multivariate observations , 1967 .

[2]  P. Jones Making Decisions , 1971, Nature.

[3]  V. Barnett,et al.  Applied Linear Statistical Models , 1975 .

[4]  J. Kalbfleisch Non‐Parametric Bayesian Analysis of Survival Time Data , 1978 .

[5]  R. Prentice,et al.  Commentary on Andersen and Gill's "Cox's Regression Model for Counting Processes: A Large Sample Study" , 1982 .

[6]  Donald Geman,et al.  Stochastic Relaxation, Gibbs Distributions, and the Bayesian Restoration of Images , 1984, IEEE Transactions on Pattern Analysis and Machine Intelligence.

[7]  M. Gail,et al.  Testing for qualitative interactions between treatment effects and patient subsets. , 1985, Biometrics.

[8]  Adrian F. M. Smith,et al.  Sampling-Based Approaches to Calculating Marginal Densities , 1990 .

[9]  R. Simon,et al.  Bayesian subset analysis. , 1991, Biometrics.

[10]  E. George,et al.  Journal of the American Statistical Association is currently published by American Statistical Association. , 2007 .

[11]  Walter R. Gilks,et al.  A Language and Program for Complex Bayesian Modelling , 1994 .

[12]  Hugh Chipman,et al.  Bayesian variable selection with related predictors , 1995, bayes-an/9510001.

[13]  J. Concato,et al.  A simulation study of the number of events per variable in logistic regression analysis. , 1996, Journal of clinical epidemiology.

[14]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .

[15]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[16]  D. Rimm,et al.  Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.

[17]  C. Robert,et al.  Optimal Sample Size for Multiple Testing : the Case of Gene Expression Mi roarraysPeter , 2004 .

[18]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Elisabeth Brambilla,et al.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. , 2006, The New England journal of medicine.

[20]  D. Ghosh,et al.  The false discovery rate: a variable selection perspective , 2006 .

[21]  J. Soria,et al.  ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Debashis Ghosh,et al.  A false‐discovery‐rate‐based loss framework for selection of interactions , 2008, Statistics in medicine.

[23]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[24]  Debashis Ghosh,et al.  Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer , 2009, Biometrics.

[25]  C. Obasaju,et al.  Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[27]  K. Chaloner,et al.  Detecting qualitative interaction: A Bayesian approach , 2010, Statistics in medicine.

[28]  S. Murphy,et al.  Variable Selection for Qualitative Interactions. , 2011, Statistical methodology.

[29]  Paul Gustafson Bayesian Analysis of Frailty Models , 2013 .